Strikingly, however, the highly prevalent occurrence of translocation breakpoints at these and several other locations predicted fusion genes such as “IGH-BCR”, “BCR-RUNX1”, “RUNX1-ABL1”, “IGH-ABL1” and “BCR-RUNX1T1” at frequencies up to 5.2%, which would have represented the third most common translocation in blood cancers (Figure 6d, Supplementary Table S2). This evidence concerns the gene ABL1 and hematopoietic and lymphoid system neoplasm.